Actinogen Medical Publishes Key Clinical Pharmacology Insights on Xanamem Actinogen Medical Limited has published an important peer-reviewed article detailing the clinical pharmacology of Xanamem, targeting Alzheimer's and depression.

Actinogen Medical Publishes Key Clinical Pharmacology Insights on Xanamem #Australia #Sydney #Actinogen_Medical #Xanamem #Emestedastat

Actinogen Medical Introduces New Nonproprietary Name for Xanamem: Emestedastat Actinogen Medical has unveiled 'emestedastat' as the new nonproprietary name for its Alzheimer's treatment, Xanamem. This strategic move is secured by the WHO's recognition and signifies a pioneering step in drug identification.

Actinogen Medical Introduces New Nonproprietary Name for Xanamem: Emestedastat #Australia #Sydney #Actinogen_Medical #Xanamem #Emestedastat

Actinogen boosts trial with Cambridge Cognition's digital suite - PharmaTimes Partnership aims to advance Alzheimer's research with innovative tools

#digitalneuroscience #brainhealth #Actinogen #ActinogenMedical #neuropsychiatricdiseases #CambridgeCognition #emestedastat #Xanamem #CANTABAttention #Alzheimersresearch #AlzheimersDisease #XanaMIAclinicaltrail #dementia #plasmabiomarker #biomarker #pTau181
pharmatimes.com/news/actinog...